Global BCG Vaccine for Prevent Covid-19 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccine for Prevent Covid-19 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
As for March, 26 2020
Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals.The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.
1.BCG Clinical Trials for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers.Another team at the university of Exeter in the UK will conduct a similar study on older people.Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine."The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help."They said.
2.Introduction of BCG
The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries.Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others.But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies.The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented.A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.
3.BCG can "Train" Innate Immunity
The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory.The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections.In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.
The global BCG Vaccine for Prevent Covid-19 market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of BCG Vaccine for Prevent Covid-19 include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of BCG Vaccine for Prevent Covid-19, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of BCG Vaccine for Prevent Covid-19 by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global BCG Vaccine for Prevent Covid-19 market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global BCG Vaccine for Prevent Covid-19 market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
InterVax
Serum Institute of India
GreenSignal
Statens Serum Institute
Shanyao Group
Shanghai Institute of Biological Products
By Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
By Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of BCG Vaccine for Prevent Covid-19 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of BCG Vaccine for Prevent Covid-19 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, BCG Vaccine for Prevent Covid-19 sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals.The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.
1.BCG Clinical Trials for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers.Another team at the university of Exeter in the UK will conduct a similar study on older people.Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine."The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help."They said.
2.Introduction of BCG
The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries.Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others.But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies.The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented.A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.
3.BCG can "Train" Innate Immunity
The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory.The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections.In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.
The global BCG Vaccine for Prevent Covid-19 market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for BCG Vaccine for Prevent Covid-19 is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of BCG Vaccine for Prevent Covid-19 include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of BCG Vaccine for Prevent Covid-19, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of BCG Vaccine for Prevent Covid-19 by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global BCG Vaccine for Prevent Covid-19 market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global BCG Vaccine for Prevent Covid-19 market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
InterVax
Serum Institute of India
GreenSignal
Statens Serum Institute
Shanyao Group
Shanghai Institute of Biological Products
By Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
By Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of BCG Vaccine for Prevent Covid-19 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of BCG Vaccine for Prevent Covid-19 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, BCG Vaccine for Prevent Covid-19 sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices